
Biochemicals control market has witnessed significant rise over the decades owing to technological advancement in healthcare industries. In a growing healthcare market where profits and growth prospects run together, many companies are vying to plunge into this untapped market. Though the healthcare industry has seen immense technological innovation over the years, the market is getting complex owing to emergence of critical healthcare illness. One such healthcare illness that has strongly affected the mankind is prostate cancer. Cases has been seen where biochemical recurrence has led to biochemical relapse, thus leading to re-emergence of prostate cancer among survivors. According to a recent study conducted by University of Wisconsin Carbone Cancer Center in Madison, USA, 35% of prostate cancer survivors are susceptible to biochemical relapse within 10 years of receiving treatment. Also, as per the World Cancer Research Fund International, prostate cancer is one of the major cause of concern globally, recording more than 1.1 million cases in 2012. Of these, 68% of the cases are recorded in developed regions. North America is the prominent region where mortality rate from prostate cancer is scaling the peak. Search for effective yet reliable technological innovation for biochemicals control in prostate cancer is offering new business horizons to healthcare industries.